Remove 2025 Remove Immunization Remove Labelling
article thumbnail

UK’s MHRA Grants Marketing Authorization for Chikungunya Vaccine

Big Molecule Watch

On February 5, 2025 Valneva SE (Valneva) announced that the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Valnevas chikungunya vaccine, IXCHIQ. Data has since shown this response can be maintained for at least three years in both younger and older adults.

article thumbnail

Getting Quality Supplements

The Thyroid Pharmacist

This is because I had learned about various adulterants found in supplements, how some supplement manufacturers don’t actually put the products that are on the label in the bottle, or that the dosages listed on the label may be completely different from what’s in the products. We have 270 expiring in March 2025.)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.

article thumbnail

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.

article thumbnail

BMS scores first approval for psoriasis therapy Sotyktu

pharmaphorum

Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. Otezla was acquired by Amgen for $13.4

article thumbnail

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

PharmaShots

We are conducting an open-label, dose-escalation, phase I/II study PDC-LUNG-101 assessing the safety, tolerability, immunogenicity, and the preliminary clinical activity of therapeutic cancer vaccine PDC*lung, associated or not with anti-PD1 treatment in patients with non-small-cell lung cancer (NSCLC). 2015; Zhu et al., 2015; Zhu et al.,

article thumbnail

Vitafoods India 2025 – Redefining and connecting the nutraceutical ecosystem to drive growth and sustainability in the industry

Express Pharma

Indias leading B2B events organiser, Informa Markets in India, is set to host the 3rd edition of Vitafoods India from February 5th to 7th 2025 at Pavilion 1-2, Jio World Convention Center, Mumbai. With Indias nutraceutical market projected to grow from USD 4 billion in 2020 to USD 18 billion by 2025, with a CAGR of 13.6

Labelling 105